Phaseline

Targets › LAT1

LAT1 (Large neutral amino acids transporter small subunit 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Jun 2028.

Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. (UniProt, Q01650)

Open in Phaseline: the race on LAT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Emory UniversityL-leucine
Competitive inhibitor of kynurenine uptake into the brain via large neutral amino acid tra
LAT1Phase 2Major DepressionJun 2028

Conditions

Major Depression (1)

Modalities

small molecule (1)

Companies

Emory University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.